Literature DB >> 21952916

Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease.

Miklos Banati1, Zsolt Hosszu, Anita Trauninger, Laszlo Szereday, Zsolt Illes.   

Abstract

INTRODUCTION: Enzyme replacement therapy (ERT) in ultra-orphan Pompe disease generates anti-rhGAA antibodies, which may interfere with efficacy.
METHODS: rhGAA-specific T-cell responses were examined at different time-points in 6 Hungarian patients treated with rhGAA and compared with 1 untreated patient and 5 healthy controls.
RESULTS: The ex vivo percentage of activated T cells was increased in treated patients. rhGAA stimulation in vitro generated a dose-dependent increase in intracellular interferon-gamma (IFN-γ) expression in CD4(+) and CD8(+) T cells. Isolated CD4(+) and CD8(+) T cells produced increased amounts of IFN-γ and tumor necrosis factor-alpha (TNF-α) in half of the patients after in vitro stimulation with rhGAA, whereas interleukin (IL)-4, IL-6, and IL-17 levels were not elevated. Expression of cytotoxic FasL and perforin molecules by natural killer (NK), NKT-like, and CD8(+) T cells were not increased ex vivo.
CONCLUSIONS: We found that enzyme replacement therapy (ERT) induces pro-inflammatory T-cell responses in addition to the antibody response in Pompe disease.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21952916     DOI: 10.1002/mus.22136

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  11 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.

Authors:  Suhrad G Banugaria; Trusha T Patel; Joanne Mackey; Stuti Das; Andrea Amalfitano; Amy S Rosenberg; Joel Charrow; Y-T Chen; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2012-01-28       Impact factor: 4.797

3.  Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice.

Authors:  Toya Ohashi; Sayoko Iizuka; Yohta Shimada; Takashi Higuchi; Yoshikatsu Eto; Hiroyuki Ida; Hiroshi Kobayashi
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

4.  Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.

Authors:  Sang-oh Han; Songtao Li; Elizabeth D Brooks; Elisa Masat; Christian Leborgne; Suhrad Banugaria; Andrew Bird; Federico Mingozzi; Herman Waldmann; Dwight Koeberl
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

Review 5.  The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.

Authors:  A Broomfield; S A Jones; S M Hughes; B W Bigger
Journal:  J Inherit Metab Dis       Date:  2016-02-16       Impact factor: 4.982

6.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

7.  Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.

Authors:  Elisa Masat; Pascal Laforêt; Marie De Antonio; Guillaume Corre; Barbara Perniconi; Nadjib Taouagh; Kuberaka Mariampillai; Damien Amelin; Wladimir Mauhin; Jean-Yves Hogrel; Catherine Caillaud; Giuseppe Ronzitti; Francesco Puzzo; Klaudia Kuranda; Pasqualina Colella; Roberto Mallone; Olivier Benveniste; Federico Mingozzi
Journal:  Sci Rep       Date:  2016-11-04       Impact factor: 4.379

8.  Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.

Authors:  Haiqing Yi; Fengqin Gao; Stephanie Austin; Priya S Kishnani; Baodong Sun
Journal:  Mol Genet Metab Rep       Date:  2016-10-04

9.  Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.

Authors:  Giorgia Squeri; Laura Passerini; Francesca Ferro; Cecilia Laudisa; Daniela Tomasoni; Federica Deodato; Maria Alice Donati; Serena Gasperini; Alessandro Aiuti; Maria Ester Bernardo; Bernhard Gentner; Luigi Naldini; Andrea Annoni; Alessandra Biffi; Silvia Gregori
Journal:  Mol Ther       Date:  2019-04-19       Impact factor: 11.454

10.  Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.

Authors:  Suhrad G Banugaria; Sean N Prater; Judeth K McGann; Jonathan D Feldman; Jesse A Tannenbaum; Carrie Bailey; Renuka Gera; Robert L Conway; David Viskochil; Joyce A Kobori; Amy S Rosenberg; Priya S Kishnani
Journal:  Genet Med       Date:  2012-10-11       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.